RET and non-small cell lung carcinoma: The calculated probability of CNS progression in brain metastasis-free patients who received selpercatinib was only 0.7% at 2 years.43 Based on results from the NSCLC cohort analysis in LIBRETTO-001, selpercatinib received its FDA approval for treatment of metastatic RET fusion-positive NSCLC in 2020.50